Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
31 hedge funds and large institutions have $3.98M invested in Nymox Pharmaceutical Corp in 2015 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 7 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
3% more funds holding
Funds holding: 30 → 31 (+1)
0% more capital invested
Capital invested by funds: $3.97M → $3.98M (+$9K)
68% less call options, than puts
Call options by funds: $77K | Put options by funds: $244K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$672K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$120K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$90.6K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$88.1K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$78.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$761K |
| 2 |
MCM
Marathon Capital Management
Hunt Valley,
Maryland
|
-$189K |
| 3 |
AL
Airain Ltd
St. Peter Port,
Guernsey
|
-$66K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$47.2K |
| 5 |
Goldman Sachs
New York
|
-$36K |
NYMX Hedge Fund Activity: Q4 2015 in Review
31 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q4 2015, worth a combined $3.98M — up 0.23% from $3.97M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new NYMX positions and 7 closed out — a net gain of 1 holder — while 9 added to existing stakes and 5 trimmed.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $672K. The largest seller was Morgan Stanley, cutting an estimated $761K.
- 31 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q4 2015, up from 30 in Q3 2015.
- Funds reported $3.98M of Nymox Pharmaceutical Corp stock for Q4 2015, up 0.23% quarter-over-quarter.
- 8 funds opened new Nymox Pharmaceutical Corp positions in Q4 2015 and 7 closed out, a net change of +1 holder.
- The largest Nymox Pharmaceutical Corp buyer in Q4 2015 was GSA Capital Partners, an estimated $672K added.
- The largest Nymox Pharmaceutical Corp seller in Q4 2015 was Morgan Stanley, an estimated $761K sold.
Based on aggregated 13F filings for Q4 2015.